---
layout: default
title: Alectinib Hydrochloride
parent: 僅模型預測 (L5)
nav_order: 31
evidence_level: L5
indication_count: 0
---

# Alectinib Hydrochloride
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Alectinib Hydrochloride: No TxGNN Predictions Available — Analysis on Hold

## One-Sentence Summary

Alectinib hydrochloride is a selective ALK/RET tyrosine kinase inhibitor, internationally approved (as Alecensa®) for the treatment of ALK-positive non-small cell lung cancer (NSCLC).
However, the current Evidence Pack contains **no TxGNN predicted indications**, making a formal repurposing evaluation impossible at this stage.
All key data inputs — including mechanism of action, safety warnings, and drug-disease predictions — are absent; a **Hold decision is recommended** until these gaps are resolved.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | No data available in this Evidence Pack |
| Predicted New Indication | No TxGNN predictions available |
| TxGNN Prediction Score | N/A |
| Evidence Level | N/A |
| Taiwan Market Status | ✗ Not Marketed (0 TFDA licenses) |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** |

---

## Why Repurposing Analysis Cannot Proceed

The Evidence Pack for alectinib hydrochloride is critically incomplete in three independent dimensions.

**First**, the `predicted_indications` array is empty — TxGNN has returned zero drug-disease repurposing candidates for this compound. Without a target indication, none of the downstream analyses (clinical trial evidence, literature review, mechanism plausibility) can be executed. This is a structural blocker: the entire report template is predicated on at least one TxGNN prediction existing.

**Second**, the mechanism of action field is flagged as a high-severity data gap (DG002). Alectinib is known in the published literature as a second-generation ALK inhibitor that suppresses ALK, RET, and ROS1 kinase activity, with CNS penetration superior to first-generation agents. However, because this information is not present in the Evidence Pack itself, it cannot be formally cited in a mechanism-plausibility argument for any repurposing candidate.

**Third**, all safety fields — key warnings, contraindications, and drug-drug interactions — are absent (DG001, Blocking severity). This prevents even the most basic safety screen required before proceeding to Stage 1 evaluation.

---

## Critical Data Gaps

| Gap ID | Category | Missing Item | Severity | Remediation |
|--------|----------|--------------|----------|-------------|
| DG001 | Drug Level | Package insert warnings and contraindications | Blocking | Download SmPC PDF from TFDA or EMA website and parse |
| DG002 | Drug Level | Mechanism of Action (MOA) | High | Query DrugBank API using INN "alectinib" |
| — | Prediction Layer | TxGNN predicted indications | Blocking | Re-run TxGNN prediction pipeline; confirm drug node mapping for alectinib hydrochloride |
| — | Identity | DrugBank ID | High | Required for all downstream collector calls (DDI, toxicity, MOA) |

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The Evidence Pack contains no TxGNN predicted indications and is missing all safety and mechanistic data. A repurposing evaluation cannot be performed without a target disease and a minimum viable safety profile.

**To proceed, the following is needed:**
- Re-run the TxGNN prediction pipeline to generate drug-disease candidates for alectinib hydrochloride, and verify that the drug node is correctly mapped in the knowledge graph
- Resolve the DrugBank ID (the query log confirms a successful DrugBank hit on 2026-03-26 — retrieve and store the ID)
- Use the DrugBank ID to populate mechanism of action and toxicity data (DG002)
- Retrieve the EU SmPC or TFDA package insert to populate warnings and contraindications (DG001)
- Re-generate the Evidence Pack once the above four items are complete, then proceed with standard L1–L5 evaluation
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

